. . . . . . . . " "@en . . "p-Amino-N-(2-diethylaminoethyl)benzamide"@en . "Avoid alcohol."@en . . . . . "Humans and other mammals"@en . "Biocoryl"@en . "For the treatment of life-threatening ventricular arrhythmias."@en . . . " "@en . "p-Aminobenzoic diethylaminoethylamide"@en . "15 to 20%"@en . . . . . . . . . . . . . . "75 to 95%"@en . . . . . . . . . . . . . . "Procainamida"@en . "approved"@en . . . . . "Take with food to reduce irritation."@en . . . . . . "Procainamide"@en . "51-06-9"@en . "A derivative of procaine with less CNS action. [PubChem]"@en . "Victor Chu, Zhu Teng, Steve Goss, Ronald Edwards, Kelle Garvey, Timothy Gorzynski, William Bedzyk, \"Synthesis and application of procainamide analogs for use in an immunoassay.\" U.S. Patent US20050227288, issued October 13, 2005."@en . . . . . "LD₅₀=95 mg/kg (rat, IV); LD₅₀=312 mg/kg (mouse, oral); LD₅₀=103 mg/kg (mouse, IV); LD₅₀=250 mg/kg (rabbit, IV)"@en . . . . . . "~2.5-4.5 hours"@en . . "Procainamide"@en . . "* 2 L/kg"@en . "Procainamidum"@en . . . . "Procainamide is sodium channel blocker. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action."@en . . "Trace amounts may be excreted in the urine as free and conjugated p-aminobenzoic acid, 30 to 60 percent as unchanged PA, and 6 to 52 percent as the NAPA derivative."@en . .